文献速递结核与非结核分枝杆菌艾滋病与性传播感染

高剂量口服与静脉利福平治疗乌干达HIV阳性成人结核性脑膜炎的II期随机对照试验

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项在乌干达开展的II期开放标签随机对照试验纳入61例疑似结核性脑膜炎成人(92% HIV阳性,中位CD4 50 cells/µL),比较标准剂量口服利福平10 mg/kg/天、静脉利福平20 mg/kg/天和高剂量口服利福平35 mg/kg/天。结果显示高剂量组血浆和脑脊液暴露显著高于标准治疗组,且未增加不良事件。

要点

  • 标准剂量利福平使89%患者脑脊液浓度低于MIC。
  • 高剂量静脉和口服利福平安全,暴露分别约为标准治疗的6倍和8倍。
  • 高剂量组93%-95%患者脑脊液浓度超过MIC。

核心结论

  • 当前国际指南导致89%的乌干达结核性脑膜炎患者脑脊液利福平浓度低于治疗水平。
  • 高剂量静脉和口服利福平安全,分别产生约6倍和8倍于标准治疗的血浆暴露,并使脑脊液浓度超过MIC。

研究设计与样本

  • II期开放标签随机对照试验,在乌干达纳入61例疑似结核性脑膜炎成人。
  • 随机分为标准治疗对照组(口服利福平10 mg/kg/天)、静脉利福平组(20 mg/kg/天)和高剂量口服利福平组(35 mg/kg/天)。
  • 在第2天和第14天进行药代动力学采样,主要结局为总暴露(AUC0-24)、最大浓度(Cmax)、脑脊液浓度和3-5级不良事件。

主要发现

  • 第2天标准治疗组血浆AUC0-24几何均值为42.9 h·mg/L,静脉20组为249 h·mg/L,口服35组为327 h·mg/L(P < .001)。
  • 标准治疗组56%参与者脑脊液利福平浓度不可测,脑脊液AUC0-24几何均值0.27 mg/L,静脉20组为1.74 mg/L(95%CI 1.2-2.5),口服35组为2.17 mg/L(1.6-2.9)(P < .001)。
  • 脑脊液浓度超过利福平MIC的比例:标准治疗组11%(2/18),静脉20组93%(14/15),口服35组95%(18/19)。
  • 第14天较高的血清和脑脊液水平仍维持。
  • 不良事件按剂量无差异(P = .34)。

临床怎么用

  • 对于HIV阳性结核性脑膜炎患者,标准剂量利福平可能不足以保证脑脊液杀菌浓度。
  • 高剂量静脉或口服利福平可考虑用于提高脑脊液暴露,但需在监测下使用。

局限性

  • II期开放标签试验,样本量较小(61例)。
  • 研究人群以HIV阳性为主(92%),CD4中位数低(50 cells/µL),结果外推需谨慎。
  • 未报告临床结局疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity. METHODS: In this phase II open-label trial, Ugandan adults with suspected TBM were randomized to standard-of-care control (PO-10, rifampicin 10 mg/kg/day), intravenous rifampicin (IV-20, 20 mg/kg/day), or high-dose oral rifampicin (PO-35, 35 mg/kg/day). We performed PK sampling on days 2 and 14. The primary outcomes were total exposure (AUC0-24), maximum concentration (Cmax), CSF concentration, and grade 3-5 adverse events. RESULTS: We enrolled 61 adults, 92% were living with HIV, median CD4 count was 50 cells/µL (interquartile range [IQR] 46-56). On day 2, geometric mean plasma AUC0-24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 327·h mg/L for PO-35 (P < .001). In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2-2.5) for IV-20 and 2.17 mg/L (1.6-2.9) for PO-35 regimens (P < .001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. Adverse events did not differ by dose (P = .34). CONCLUSIONS: Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. High-dose intravenous and oral rifampicin were safe and respectively resulted in exposures ~6- and ~8-fold higher than standard of care, and CSF levels above the MIC.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cresswell FV, Meya DB, Kagimu E, et al. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis. 2021. PMID: 33693537. doi:10.1093/cid/ciab162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。